Why medtech deals stall
- Posts from medtech-focused accounts broke down why hospital purchases often fail between clinical validation and procurement. - Common pitfalls include poor workflow fit, misaligned economic stories, and long stakeholder cycles unique to healthcare buying. - The advice emphasises tailoring B2B sales motions to clinical evidence, procurement timelines, and compliance hurdles rather than generic SaaS playbooks. (x.com/RedHouseUSA, x.com/Deepak_AvairAI)
A medtech sale can clear clinical validation and still die inside a hospital because the buying test is no longer just “does it work.” (ahrmm.org) Most hospital systems now route new products through value analysis, a cross-functional review that weighs clinical outcomes, quality, workflow, contracting, and cost before procurement moves ahead. (ahrmm.org, symplr.com) That means a physician champion is rarely enough on its own. Symplr says a product typically must clear four gates: Food and Drug Administration approval, clinician demand, payer reimbursement, and hospital purchase approval. (symplr.com) The shift is structural, not cosmetic. Medical Product Outsourcing reported in March 2023 that value analysis committees have been the norm in hospital purchasing for about 20 years, replacing a model where physician preference carried more weight. (mpo-mag.com) Hospitals built those committees under cost pressure and outcome pressure at the same time. Symplr says physician-preferred items account for 40% to 60% of hospital supply costs, giving supply chain and finance leaders a direct reason to scrutinize every new device. (symplr.com) That scrutiny reaches beyond price. Medical Product Outsourcing said successful vendors now have to answer three questions for economic and clinical buyers: whether the device improves outcomes, fits standardized workflows and care protocols, and lowers contracted supply costs. (mpo-mag.com) Workflow fit is where many deals slow down. ECRI wrote in February 2025 that a device can look strong on paper but still fail after purchase if it adds steps, forces training, creates interface problems, or requires changes to staffing and maintenance. (ecri.org) Hospital buying also stretches across more people than a typical software sale. AHRMM’s procurement training materials frame the job as balancing cost, quality, and outcomes through purchasing, sourcing, contracting, negotiation, vendor management, and legal review. (ahrmm.org) That is why generic business-to-business software tactics often miss in medtech. A hospital committee can like the clinical data and still pause a purchase over reimbursement, compliance, contracting terms, training burden, or a weak economic case for the health system. (symplr.com, ahrmm.org, ecri.org) The practical lesson is narrower than “sell harder.” In hospital procurement, the companies that move deals forward are the ones that show evidence a device works, evidence it fits the care team’s daily routine, and evidence the system can afford to adopt it. (mpo-mag.com, ahrmm.org, ecri.org)
